Vol 8: Drug delivery options to increase patient adherence and satisfaction in the management of rheumatoid arthritis - focus on subcutaneous tocilizumab.Report as inadecuate



 Vol 8: Drug delivery options to increase patient adherence and satisfaction in the management of rheumatoid arthritis - focus on subcutaneous tocilizumab.


Vol 8: Drug delivery options to increase patient adherence and satisfaction in the management of rheumatoid arthritis - focus on subcutaneous tocilizumab. - Download this document for free, or read online. Document in PDF available to download.

Download or read this book online for free in PDF: Vol 8: Drug delivery options to increase patient adherence and satisfaction in the management of rheumatoid arthritis - focus on subcutaneous tocilizumab.
This article is from Drug Design, Development and Therapy, volume 8.AbstractRheumatoid arthritis (RA) is a chronic, progressive, inflammatory disease associated with joint destruction. Tocilizumab (TCZ) is a humanized monoclonal anti-interleukin-6 receptor antibody that was initially developed for use as an intravenous (IV) infusion. Previous studi

Author: Nakashima, Yasuharu; Kondo, Masakazu; Miyahara, Hisaaki; Iwamoto, Yukihide

Source: https://archive.org/







Related documents